Shinji Asada

8PUBLICATIONS
9CO-AUTHORS
PharmacogenomicsClinical pharmacology and therapeuticsEpidemiological modellingPharmaceutical delivery technologiesMedical biochemistry - inorganic elements and compounds
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 28, 2026
Patient characteristics associated with the need for high doses of tenapanor hydrochloride in dialysis patients with hyperphosphatemia: A pooled analysis of three clinical trials.

|Dec 22, 2023
Real-world evidence on levodopa dose escalation in patients with Parkinson's disease treated with istradefylline.

Nobutaka Hattori, Daijiro Kabata, Shinji Asada

|Dec 13, 2022
Predictive factors requiring high-dose evocalcet in hemodialysis patients with secondary hyperparathyroidism.

Masanori Tokumoto, Shin Tokunaga, Shinji Asada

|Feb 17, 2022
Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism.

Takashi Shigematsu, Shinji Asada, Yuichi Endo

|Oct 13, 2020
Changes in 3-month mineral and bone disorder patterns were associated with all-cause mortality in prevalent hemodialysis patients with secondary hyperparathyroidism.

Chihiro Kato, Naohiko Fujii, Chisato Miyakoshi

|Jun 05, 2020
Efficacy and Safety of Evocalcet Evaluated by Dialysate Calcium Concentration in Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis.

Takashi Shigematsu, Shinji Asada, Yuichi Endo

Pageof 2

Frequent Collaborators

2 joint publications

Takashi Shigematsu

1 joint publications

Takehisa Kawata

1 joint publications

Masafumi Fukagawa

1 joint publications

Tadao Akizawa